🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

"The alleged benefits of these maneuvers were frequently lost on patients whose worsening dyspnoea left the with little energy to debate with their surgeons" Sounds like most of my on calls...

Tons of information in this study + needs a careful read. Low rate of major comps and impressive length of stay *bbuutt* 50% of Obesity class III were ASA I/II, 93% had open surgery, 70% no fundo & x2 as many minor comps. Maybe high BMI should trigger a case-by-case approach?

Was quite touched to be asked to write this for ASCO. Has immunotherapy put the nail in the coffin for oligometastatic SCC? dailynews.ascopubs.org/do/approach-tr… Have a read and decide! jonathan Cools

Great to see this published. We need to consider the physical strain on operating surgeons as a core endpoint to the evaluation of new technology including robotics. Nuffield Department of Surgical Sciences Strain on the surgeon: a systematic review of the methods of measuring... sciencedirect.com/science/articl…

I'm not sure where else in medicine we would call a 30% failure rate at 1 year a 'safe alternative' approach. thelancet.com/journals/langa…

Hot off the press! "International Society for Diseases of the Esophagus consensus on management of the failed fundoplication" #GERD #SoMe4Surgery #ISDE #EsophagealSurgery ow.ly/qWpL50Vr3wj

I'm not a big conference guy but this is *the* meeting for all things upper GI...its a long way but worth it ! ISDE.net

Great seeing this manuscript in print on patient-specific esophagus cancer-organ chip. Complete clinical mimicry Excellent work by ⁦Sanjima⁩ ⁦Research Institute of the MUHC (The Institute)⁩ with collaboration with ⁦Wyss Institute⁩ ⁦Don Ingber⁩ …nslational-medicine.biomedcentral.com/articles/10.11…

Don't let it pass under the radar! Organ chip is hugely important in eso cancer where the complex immuno-environment is making the implementation of immunotherapy challenging! This research will help unravel that Hugely talented team McGillThoracic Sanjima Lorenzo Ferri MD PhD

This is a really important document, helping to guide surgeons how to manage these challenging cases...maybe it could be followed by a technical paper exploring aspects of redo surgery ?

Presented at #ASCO25: In resectable gastric and gastroesophageal junction cancer, adding durvalumab to perioperative chemotherapy improved event-free survival and pathological complete response, with no major increase in high-grade adverse events. Full MATTERHORN trial

This is the data that many of us have been waiting for. Whilst exciting, epoch changing it is not...should we be focusing on personalising care rather than still trying to make a square peg fit a round hole?

It seems we are in a bit of a data quagmire. I often get asked how to choose between neoadjuvant versus perioperative immunotherapy and right now there aren’t many great answers, but for what it’s worth, here’s my general perspective… #ASCO25

Guess that means I'm off to Australia for a couple of days ! See you there Lorenzo Ferri MD PhD Magnus Nilsson Sheraz Markar

Whoever is in Montreal, I strongly suggest attending this meeting...rubbing shoulders with leaders in the Mx on lung cancer

Kinda neat technique...never seems to be a good way to manage these patients so good to have another approach in the tool box!

Bought my ticket to ISDE....just hoping I will be able to get there ! ISDE.net !!

Join us Wednesday, July 16, for “Best of Esophageal” highlights from the AATS 2025 annual meeting! aats-org.zoom.us/webinar/regist…

So excited to see this paper on the stromal changes driving Barrett’s Esophagus progression to Cancer. A Herculean effort effort integrating scRNASeq/CODEX/ECM proteomics. Concerted changes in Epithelium and Stroma: a multi-scale, multi-omics... sciencedirect.com/science/articl…

📣 Excited to share our lab's latest preprint, detailing a comprehensive study on longitudinally collected GEA patient-derived #organoids #CAFs #TILs. This work represents a significant step forward in modeling GEA-TME & personalized treatment responses.